Bart Keymeulen

Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes

Bart Keymeulen, Evy Vandemeulebroucke, Anette G. Ziegler et al. · New England Journal of Medicine · 2005 · 1.1K citations · Full text

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 498 citations

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

Bart Keymeulen, Melanie Walter, Chantal Mathieu et al. · Diabetologia · 2010 · 310 citations · Full text

Obesity, Metabolic Syndrome, Diabetes Management +12

Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes

Gabriëlle G.M. Pinkse, Odette H. M. Tysma, Cees A. M. Bergen et al. · Proceedings of the National Academy of Sciences · 2005 · 277 citations · Full text

Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient

Daniel Jacobs‐Tulleneers‐Thevissen, Marie Chintinne, Z. Ling et al. · Diabetologia · 2013 · 226 citations · Full text

Regenerative Medicine, Tissue Engineering, Type 1 +11